Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis Role of B Cells in EAE
2011

Rituximab Therapy and Its Effects on T Cell Responses in Autoimmune Encephalomyelitis

publication Evidence: moderate

Author Information

Author(s): Monson Nancy L., Cravens Petra, Hussain Rehana, Harp Christopher T., Cummings Matthew, de Pilar Martin Maria, Ben Li-Hong, Do Julie, Lyons Jeri-Anne, Lovette-Racke Amy, Cross Anne H., Racke Michael K., Stüve Olaf, Shlomchik Mark, Eagar Todd N.

Primary Institution: University of Texas Southwestern Medical Center

Hypothesis

What is the impact of Rituximab on T cell responses in experimental autoimmune encephalomyelitis (EAE)?

Conclusion

Rituximab treatment reduces the severity of EAE by depleting B cells and altering T cell responses.

Supporting Evidence

  • Rituximab administration rapidly depleted peripheral B cells.
  • B cell depletion was associated with diminished T cell proliferation.
  • EAE severity was significantly reduced in mice treated with Rituximab.
  • Rituximab treatment altered T cell responses in the spleen and CNS.

Takeaway

Rituximab helps treat a disease by removing certain immune cells, which makes the disease less severe.

Methodology

The study used a mouse model of EAE to assess the effects of Rituximab on B and T cell responses.

Limitations

The study was conducted in a mouse model, which may not fully replicate human disease.

Statistical Information

P-Value

p<0.02

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0017103

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication